Impact of kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins

Journal of Infectious Diseases

Volumn 192, Issue 4, 2005, Pages 622-629

  Woodberry, Tonia ^a   Suscovich, Todd J ^a   Henry, Leah M ^a   Martin, Jeff N ^c   Dollard, Sheila ^f   O'Connor, Paula G ^a   Davis, Jennifer K ^a   Osmond, Dennis ^c   Lee, Tzong Hae ^d   Kedes, Dean H ^e   Khatri, Ashok ^a   Lee, Jeannette ^g   Walker, Bruce D ^a,b   Scadden, David T ^a   Brander, Christian ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; PREDNISONE; PROTEIN ORF65; PROTEIN ORF73; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS ANTIGEN; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN ANALYSIS; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION; VIRUS CHARACTERIZATION; VIRUS DIAGNOSIS; VIRUS INFECTION;

ANTIGENS, VIRAL; CAPSID PROTEINS; FEMALE; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MALE; NUCLEAR PROTEINS; SARCOMA, KAPOSI; T-LYMPHOCYTES; VIRAL PROTEINS;

EID: 23244456455     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432103     Document Type: Article

References (45)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91.
2. Cattelan AM, Calabro ML, Aversa SM, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999; 35:1809-15.
3. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-6.
4. Novitsky V, Gilbert P, Peter T, et al. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 2003; 77:882-90.
5. Piriou ER, van Dort K, Nanlohy NM, Miedema F, van Oers MH, van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol 2004; 172:6931-7.
6. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-200.
7. + T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298-305.
8. Jin X, Ogg G, Bonhoeffer S, et al. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol Med 2000; 6:803-9.
9. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485-93.
10. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996; 93:14862-7.
11. +- T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:6104-13.
12. Brander C, O'Connor P, Suscovich T, et al. Definition of an optimal cytotoxic T lymphocyte epitope against the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis 2001; 184:119-26.
13. Brander C, Raje N, O'Connor PG, et al. Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. Blood 2002; 100:698-700.
14. + cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. J Infect Dis 2000; 182:928-32.
15. + T-cell response to viral lytic cycle proteins. Blood 2001; 97:2366-73.
16. + T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood 2002; 99:3360-6.
17. Stebbing J, Bourboulia D, Johnson M, et al. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol 2003; 77:4306-14.
18. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76:2634-40.
19. Micheletti F, Monini P, Fortini C, et al. Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology 2002; 106:395-403.
20. Osman M, Kubo T, Gill J, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 1999; 73:6136-40.
21. Pellett PE, Wright DJ, Engels EA, et al. Multicenter comparison of serologid assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 2003; 43:1260-8.
22. Engels EA, Whitby D, Goebel PB, et al. Identifying human herpesvirus 8 infection: performance characteristics of serologic assays. J Acquir Immune Defic Syndr 2000; 23:346-54.
23. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996; 348:1133-8.
24. Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996;2:918-24.
25. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948-54.
26. Martin JN, Osmond DH. Determining specific sexual practices associated with human herpesvirus 8 transmission. Am J Epidemiol 2000; 151:225-9.
27. Martro E, Bulterys M, Stewart JA, et al. Comparison of human herpesvirus 8 and Epstein-Barr virus seropositivity among children in areas endemic and non-endemic for Kaposi's sarcoma. J Med Virol 2004; 72:126-31.
28. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-9.
29. Rezza G, Andreoni M, Dorrucci M, et al. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst 1999;91:1468-74.
30. Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847-51.
31. Martro E, Cannon MJ, Dollard SC, et al. Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection. J Virol 2004; 78:11707-14.
32. Chandra A, Demirhan I, Massambu C, et al. Cross-talk between human herpesvirus 8 and the transactivator protein in the pathogenesis of Kaposi's sarcoma in HIV-infected patients. Anticancer Res 2003; 23:723-8.
33. Merat R, Amara A, Lebbe C, de The H, Morel P, Saib A. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer 2002; 97:791-5.
34. Martinez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002; 14:528-32.
35. Hay CM, Ruhl DJ, Basgoz N, et al. Lack of viral escape and defective in vivo activation of HIV-1-specific CTL in rapidly progressive infection. J Virol 1999; 73:5509-19.
36. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000; 165:1082-92.
37. Draenert R, Verrill CL, Tang Y, et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 2004; 78:630-41.
38. Means RE, Choi JK, Nakamura H, Chung YH, Ishido S, Jung JU. Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus. Curr Top Microbiol Immunol 2002; 269:187-201.
39. Brander C, Suscovich T, Lee Y, et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma associated herpes virus (KSHV/ HHV8). J Immunol 2000; 165:2077-83.
40. Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest 2001; 107:1599-606.
41. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci USA 2000; 97:8051-6.
42. Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000; 343:1369-77.
43. Quinlivan EB, Wang RX, Stewart PW, et al. Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS. J Med Virol 2001; 64:157-66.
44. Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5:87-103.
45. Lopalco L. Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? Curr HIV Res 2004; 2:127-39.